Akut Bronşiolitli Çocuklarda Human Paraoksonaz-1 Aktivitesi

Yıl 2020, Cilt: 18 Sayı: 3, 336 - 345, 18.12.2020

Ufuk Erenberk Feyza Ustabaş Kahraman Mehmet Emin Özkaya Mustafa Atilla Nursoy Ayşegül Doğan Demir Özden Türel

Öz

GİRİŞ ve AMAÇ: Human paraoksonaz-1 (PON1), oksidatif strese karşı çalışan endojen antioksidan moleküllerden biridir. Bu çalışmada akut bronşiolitli çocuklarda serum PON1 aktivitesini araştırmayı amaçladık.

YÖNTEM ve GEREÇLER: Akut bronşiyolitli 3-21 aylık 29 çocuk ile yaş uyumlu 35 sağlıklı kontrol çalışmaya dahil edildi. Bronşiolit hastaları hafif (% 65) ve orta (% 35) olarak sınıflandırıldı. Akut bronşiolitli hastalar ile kontrol grubu arasında PON1'in paraoksonaz ve arilesteraz aktiviteleri karşılaştırıldı.

BULGULAR: Akut bronşiyolitli çocukların paraoksonaz aktivitesi sağlıklı kontrollere göre daha düşüktü, ancak fark anlamlı değildi (127.53 ± 64.17 U / L'ye karşı 153.95 ± 74.40 U / L) (p = 0.13). Hafif ve orta derecede bronşiyolitli çocuklarda arilesteraz aktivitesi kontrol grubuna göre anlamlı olarak daha azdı (142.43 ± 56.60 kU / L ve 103.05 ± 26.03 kU / L'ye karşılık 201.09 ± 57.26 kU / L) (p <0.001).

TARTIŞMA ve SONUÇ: Akut bronşiolitli çocuklarda serum PON1 aktivitesi kontrol grubuna göre daha düşüktü. Antioksidan kapasitenin arttırılması, viral kaynaklı akciğer hastalığında etkili bir tedavi aracı olabilir

Anahtar Kelimeler

oksidatif stres,, çocuk, bronşiolit, Paraoksonaz-1 Aktivitesi

Human Paraoxonase-1 Activity in Children with Acute Bronchiolitis

Öz

INTRODUCTION: Human paraoxonase-1 (PON1) is one of the endogenous antioxidant molecules working against oxidative stress. We aimed to investigate serum PON1 activity in children with acute bronchiolitis.

MATERIALS and METHODS: A total of 29 children aged between 3-21 months with acute bronchiolitis and 35 age-matched healthy controls were included in the study. Bronchiolitis patients were further classified as mild (65%) and moderate (35%). Paraoxonase and arylesterase activities of PON1 were compared between patients with acute bronchiolitis and the control group.

RESULTS: Paraoxonase activity of children with acute bronchiolitis was lower than healthy controls but the difference was not significant (127.53 ± 64.17 U/L versus 153.95 ± 74.40 U/L) (p=0.13). Arylesterase activity was significantly decreased in children with mild and moderate bronchiolitis in comparison to the control group (142.43± 56.60 kU/L and 103.70± 26.03 kU/L versus 201.09± 57.26 kU/L) (p<0.001).

CONCLUSIONS: Serum PON1 activity was lower in children with acute bronchiolitis compared to controls. Increasing antioxidant capacity may be an effective means of therapy in viral induced lung disease.

Anahtar Kelimeler

paraoxonase, arylesterase,, oxidative stress

Kaynakça

• 1. 1. Carroll KN, Gebretsadik T, Griffin MR, et al. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics 2008;122:58-64.
• 2. 2. Ali S, Plint AC, Klassen TP. 2012. Bronchiolitis; in Wilmott RW, Boat TF, Bush A, Chernick V, Deterding RR, Ratjen F (eds). Kendig and Chernick’s Disorders of the Respiratory Tract in Children; 2012. pp. 443–52.
• 3. 3. Ciencewicki J, Trivedi S, Kleeberger SR. Oxidants and the pathogenesis of lung diseases. J Allergy Clin Immunol 2008; 122:456-68.
• 4. 4. Park HS, Kim SR, Lee YC. Impact of oxidative stress on lung diseases. Respirology 2009;14:27-38.
• 5. 5. Owen S, Pearson D, Suarez-Mendez V, et al. Evidence of free-radical activity in asthma. N Engl J Med 1991;325:586-7.
• 6. 6. Cemek M, Caksen H, Bayiroğlu F, et al. Oxidative stress and enzymic-non-enzymic antioxidant responses in children with acute pneumonia. Cell Biochem Funct 2006;24:269-73.
• 7. 7. Hosakote YM, Jantzi PD, Esham DL, et al. Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2011;183:1550-60.
• 8. 8. Gurkan F, Atamer Y, Ece A, et al. Relationship among serum selenium levels, lipid peroxidation, and acute bronchiolitis in infancy. Biol Trace Elem Res 2004;100:97-104.
• 9. 9. Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr 1996;16: 33-50.
• 10. 10. Van Himbergen TM, Van Tits LJ, Roest M, et al. The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 2006;64;34-8.
• 11. 11. Blatter MC, James RW, Messmer S, et al. Identification of a distinct human high-density lipoprotein subspe¬cies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993;211:871–9.
• 12. 12. Rodrigo L, Hernández AF, López-Caballero JJ, et al. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 2001;137:123-37.
• 13. 13. Apostolou F, Gazi IF, Lagos K, et al. Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes. Atherosclerosis 2010;212:607-13.
• 14. 14. Selek S, Cosar N, Kocyigit A, et al. PON1 activity and total oxidant status in patients with active pulmonary tuberculosis. Clin Biochem 2008;41:140-4.
• 15. 15. Aslan M, Nazligul Y, Horoz M, et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis 2008;196:270-4.
• 16. 16. Górnicka G, Bełtowski J, Wójcicka G, et al. Serum paraoxonase activity, total antioxidant potential and lipid peroxidation products in children with bronchial asthma exacerbation. Wiad Lek 2002;55:257-63.
• 17. 17. Koc S, Aksoy N, Bilinc H, et al. Paraoxonase and arylesterase activity and total oxidative/ anti-oxidative status in patients with chronic adenotonsillitis. Int J Pediatr Otorhinolaryngol 2011;75:1364-7.
• 18. 18 Lakhanpaul M, Armon K, Eccleston P, et al. An evidence based guideline for the management of children presenting with acute breathing difficulty. Nottingham University, Available from; http://www.nottingham.ac.uk/paediatric-guideline/breathingguideline.pdf Accessed, 15 March 2019.
• 19. 19. Ozturk E, Balat O, Dikensoy E, et al. No association between serum paraoxonase, arylesterase activities, and hydatidiform mole. Int J Gynecol Cancer 2011;21:149- 52.
• 20. 20. Mackness MI, Arrol S, Abbot C, et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35.
• 21. 21. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304-16.
• 22. 22. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001;103:2283-8.
• 23. 23. Campbell LA, Yaraei K, Van Lenten B. The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis. Microbes Infect 2010;12:598-606.
• 24. 24. Rosenblat M, Gaidukov L, Khersonsky O, et al. The catalytic histidine dyad of high density lipopro¬tein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimu¬lation of macrophage cholesterol efflux. J Biol Chem 2006;281:7657–65.
• 25. 25. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005;44:6371-82.
• 26. 26. Camps J, Pujol I, Ballester F, et al. Paraoxonases as potential antibiofilm agents: their relationship with quorum-sensing signals in Gram-negative bacteria. Antimicrob Agents Chemother 2011;55:1325-31.
• 27. 27. Nguyen SD, Sok DE. Oxidative inactivation of paraoxonase 1, an antioxidant protein and its effect on antioxidant action. Free Radic Res 2003;37:1319-30.
• 28. 28. James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004;37:1986-94.
• 29. 29. Gruber M, Christ-Crain M, Stolz D, et al. Prognostic impact of plasma lipids in patients with lower respiratory tract infections - an observational study. Swiss Med Wkly 2009;139:166-72.
• 30. 30. Novak F, Vavrova L, Kodydkova J, et al. Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med 2010;10:21-5.
• 31. 31. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26:892-904.
• 32. 32. Da Costa LA, Badawi A, El-Sohemy A. Nutrigenetics and modulation of oxidative stress. Ann Nutr Metab 2012; 60 Suppl 3:27-36. Epub 2012 May 15.
• 33. 33. Kunes JP, Cordero-Koning KS, Lee LH, Lynch SM. Vitamin C attenuates hypochlorite-mediated loss of paraoxonase-1 activity from human plasma. Nutr Res 2009;29:114-22.
• 34. 34. Bose KS, Agrawal BK. Effect of lycopene from cooked tomatoes on serum antioxidant enzymes, lipid peroxidation rate and lipid profile in coronary heart disease. Singapore Med J 2007;48:415-20.